Corcept Therapeutics

246 articles about Corcept Therapeutics

• Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call

  2/8/2022

  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022.

• Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer

  12/16/2021

  Corcept Therapeutics Incorporated today announced the preliminary results of its previously announced tender offer to purchase up to 10,000,000 shares of its common stock, par value $0.001 per share.

• Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares

  12/15/2021

  Corcept Therapeutics Incorporated announced an update to its offer to purchase up to 10,000,000 shares of its common stock at a price not greater than $23.75 nor less than $20.75 per share closing at one minute after 11:59 P.M., New York City time, on December 15, 2021.

• Corcept Therapeutics Announces Extension of Previously Announced Tender Offer

  12/8/2021

  Corcept Therapeutics Incorporated today announced that it has extended the expiration of its previously announced tender offer for shares of its common stock from one minute after 11:59 P.M., New York City time, on December 7, 2021 until one minute after 11:59 P.M., New York City time, on December 15, 2021 (unless further extended or earlier terminated).

• Corcept Therapeutics to Present at Upcoming Investor Conferences

  11/10/2021

  Corcept Therapeutics Incorporated today announced that the company will present at the following investor conferences: Jefferies London Healthcare Conference Date: Tuesday, November 16, 2021 Presentation Time: 5:00 pm GMT

• Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 10 Million Shares of its Common Stock

  11/8/2021

  Corcept Therapeutics Incorporated today announced that it has commenced a modified Dutch Auction tender offer for the purchase of up to 10 million shares of Corcept’s common stock, par value $0.001 per share

• Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update

  11/3/2021

  Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended September 30, 2021.

• Corcept Therapeutics to Announce Third Quarter 2021 Financial Results, Provide Corporate Update and Host Conference Call

  10/27/2021

  Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 3, 2021.

• Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer

  9/17/2021

  Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial featured in a proffered paper oral presentation at ESMO 2021

• Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

  7/29/2021

  Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended June 30, 2021.

• Corcept Therapeutics To Announce Second Quarter 2021 Financial Results, Provide Corporate Update and Host Conference Call

  7/22/2021

  Corcept Therapeutics Incorporated announced it will report second quarter financial results and provide a corporate update on July 29, 2021.

• Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

  6/22/2021

  Corcept Therapeutics today announced preliminary results from its Phase 3 RELIANT trial of relacorilant combined with nab-paclitaxel in patients with metastatic pancreatic cancer.

• Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical

  6/15/2021

  Corcept Therapeutics Incorporated today announced that it has entered into an agreement with Sun Pharmaceutical Industries Limited and related entities ("Sun") resolving patent litigation related to Korlym.

• Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors

  6/10/2021

  Corcept Therapeutics Incorporated announced today that Joshua M. Murray has joined the company’s Board of Directors.

• Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)

  5/6/2021

  Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, announced interim findings from the Phase 2 trial of its selective cortisol modulator miricorilant in patients with presumed NASH.

• Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer

  5/6/2021

  Women with platinum resistant ovarian cancer experienced longer progression free survival with relacorilant plus nab-paclitaxel than with nab-paclitaxel alone

• Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess

  3/15/2021

  Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in the Phase 1b trial of relacorilant in combination with the PD-1 checkpoint inhibitor pembrolizumab (Merck’s medication, Keytruda ® )

• Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results

  2/23/2021

  Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter- and year-ended December 31, 2020.

• Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update

  2/8/2021

  Financial Highlights, 2021 Revenue Guidance and Legal Update Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019 Preliminary fourth quarter revenue $85.7 million, compared to $87.9 million in fourth quarter 2019 2021 revenue guidance $375 - 405 million Preliminary 2020 fully diluted GAAP net income $0.85 per share, compared to $0.77 per share in 2019 Preliminary fourth quarter fully diluted GAAP net income $0.20 per share, compared to $0.24 per share

• Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call

  2/1/2021

  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results and provide a corporate update on February 8, 2021